- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Pharma Pulse 11/7/24: Women Within Health Care Face Financial Disparities, The New Frontier for Clinical Research Excellence & more
The latest news for pharma industry insiders.
Site QMS-Based Site Monitoring: The New Frontier for Clinical Research Excellence
Moving towards the development of mature quality management systems.
Women Within Health Care Face Financial Disparities and Are More Likely to Experience Burnout
The authors believe that improvements can be made to overlook the motherhood penalty and its associated pay gaps as well as changes to address workforce burnout.
Election Wargames: Tech and Politics Try Their Hands at Detecting Voting Threats
‘Risk games’ hosted by Lux Capital expose the difficulty of identifying technology-related election threats.
The "Cancer Antibody Drug Conjugates Market Size, Drugs Approval, Price, Sales & Clinical Trials Insight 2030" report has been added to ResearchAndMarkets.com offering.
The rapid evolution of antibody drug conjugates reflects their clinical and commercial success, with 16 products currently approved across various markets and sales surpassing US$ 10 Billion in 2023 and US$ 7 Billion in the first 6 months of 2024. This growth highlights antibody drug conjugates as a commercially viable segment of the broader cancer therapeutics market, prompting increased research and development efforts to create more effective and safer candidates.
How are pharma supply chains adapting to new regulations and industry trends? Kenco’s VP of Life Sciences, Tim McClatchy, outlines three key challenges in Pharmaceutical Commerce Magazine. Dive into the details here!
#lifesciences #PharmaceuticalCommerce #supplychain #3pl #Kenco
Have news you want us to share in Pharma Pulse? Reach out to Social Media Editor Miranda Schmalfuhs
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
Johnson & Johnson Seeks FDA Approval for Subcutaneous Tremfya Regimen for Ulcerative Colitis
November 22nd 2024Johnson & Johnson has submitted a supplemental Biologics License Application to the FDA for a subcutaneous induction regimen of Tremfya for adults with moderately to severely active ulcerative colitis based on positive Phase III ASTRO trial results.
